Volume: 4 Issue: 3
Year: 2016, Page: 12-16,
Introduction: Allergic rhinitis is a disease of the mucous membranes of the nasal airways. Proinflamatory mediators like histamine, leukotrienes, Platelet activating factor (PAF) play a vital role in pathogenesis. Fexofenadine, an antihistaminic and Rupatadine a H1 receptor and PAF antagonist are used in the present study and their safety and efficacy were compared.
Objectives:The rationale of this study was to evaluate whether Rupatadine or Fexofenadine was better in the treatment of allergic rhinitis.
Materials and Methods :The present study comprised of a total of 100 patients with typical features of allergic rhinitis. They are divided into 2 groups of 50 patients each,group 1 is treated by Rupatadine and group 2 by Fexofenadine. Patients in the age group of 16-45 years of both sexes were included in the study and the duration of these symptoms had to be of at least one month or more to rule out common cold or other minor infections of the upper respiratory tract.
Results: Rupatadine had a slightly more edge in comparison to Fexofenadine in controlling the symptoms of the allergic rhinitis. Reduction of IgE levels, suppression of Absolute eosinophil count and radiographic evidence of improvement of maxillary sinuses was better with Rupatadine.
Conclusion:Though the results in our study did not show statistically significant difference between the two drugs, clinical efficacy and safety of Rupatadine in allergic rhinitis was clearly outweighing Fexofenadine. Considering all the above factors, Rupatadine appears to be a better choice in the treatment of allergic rhinitis as compared with Fexofenadine.
Keywords: Allergic rhinitis, Fexofenadine, Platelet activating factor, Rupatadine
1. D.S. Deendayal. Nasal Allergy-Dissertation submitted for M.S (Otorhinolaryngology) of Osmania University, January 1983.
2. Skoner DP. Allergic rhinits: definition, epidemiology, pathophysiology, detection diagnosis. Journal of Allergy and Clinical Immunology (2001); 108 (Suppl): S2–S8.
3. Boulay ME, Boulet LP et al. The relationships between atopy, rhinitis and asthma: Pathophysiological considerations. Current Opinion in Allergy and Clinical Immunology 2003; 3: 51 – 55.
4. Shoenwetter WF, Dupclay Jr L, Appayjosyula S, Botteman MF, Pashos CL et al. Economic impact and quality of life burden of allergic rhinitis. Cur. Med. Res. Opin. 2004;20: 305 – 17.
5. Yamada Y, Yokota M. Roles of plasma platelet activating factor acetyl hydrolase in allergic, inflammatory and atheroscleoritic diseases. Jpn. Circ. J. 1998; 62:328 – 335.
6. Sciberras DG, Bolognese JA, Goldemberg MM, James I, Baber NS. Platelet activating factor induced inflammatory responses in the skin. Prostaglandins 1988;35: 833.
7. Synder F. Metabolic processing of PAF. Clin. Rev. Allergy 1994 ;12: 309 – 27.
8. Prescott SM, Zimmerman GA, Mcintyre TM. The production of platelet activating factor by cultured human endothelial cells; regulation and function in Platelet Activating Factor and related Lipid Mediators – Synder F (ed): New York, Plenumpress 1987;323 – 340.
9. Velero A, Serranoc, Bartra. Safety of Rupatadine administered over a period of 1 year in the treatment of perennial allergic rhinitis; a multicentre open label study in Spain. Drug Saf 2009; 32 – 42.
10. Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of Rupatadine in Allergic Rhinitis. Primary Care Respiratory Journal 2009;18 (2); 57 – 68.
11. David A Axelrod, Bielory L. Fexofenadine hydrochloride in the treatment of Allergic disease: A review. Journal of Asthma and Allergy Sep 2008; 19 - 28.
12. Terrien MH, Rahm F, Fellrath JM, Spertini F. Comparision of the effects of Terfenadine with Fexofenadine on nasal provocation tests with allergen; Journal of Allergy and Clinical Immunology 1999;103(6): 1025 - 1030.
13. Simons FER, Simons KJ. Peripheral H1-blockade effect of Fexofenadine. Ann Allergy Asthma Immunol 1997; 79: 530-532.
14. Bronsky EA, Falliers CJ, Kaiser HB, Ahlbrandt R, Mason JM. Effectiveness and safety of Fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of all allergies. Allergy Asthma Proceed 1998; 19(3): 135-141.
15. Pfaar O, Raap U, Holz M, Hormann K, Klimek L. Pathophysiology of itching and sneezing in allergic rhinitis. Swiss Med Wkly 2009; 139(3 – 4): 35 – 40.
16. Cocera CM, M. De Molina, E. Martí-Guadano , J. Pola , J. Conde, J. Borja, et.al. Rupatadine 10 mg and Cetirizine 10 mg in seasonal allergic rhinitis: A randomised, doubleblind parallel study. J Invest Allergol Clin Immunol 2005; Vol 15(1): 22 - 29.
17. Maiti R, Rahman J, Jaida J, Allala U, Palani A. Rupatadine and Levocetirizine for seasonal allergic rhinitis: a comparative Allergy 2004; 59: 766 – 771.
18. Maiti R, Jaida J, Rahman J, Gaddam R, Palani A. Olopatadine hydrochloride and Rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety. J Pharmacology Pharmacotherapy. Oct-Dec 2011; 2(4): 270–276.
19. Martin S F, Dumur JP, Perez I, Izquierdo I. A randomized, double-blind, parallel-group study, comparing the efficacy and safety of Rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to Loratadine 10 mg in the treatment of seasonal allergic rhinitis. J Invest Allergol Clin Immunol 2004; 14(1): 34-40.
20. Guadano EM, Serra – Batlles J, Meseguer J, Castillo JA, De Molina M, Volero A et al. Rupatadine 10mg and Ebastine 10mg in seasonal allergic rhinitis; A comparison study.
21. Day JH, Briscoe MP, Rafeiro E, Ratz JD, Ellis AK, Frankish CW, et al. Comparative efficacy of cetirizine and fexofenadine for seasonal allergic rhinitis, 5-12 hours post dose,in the environmental exposure unit.Allergy Asthma Proc. Jul-Aug 2005 Jul-Aug;26(4):275-82.
22. Cauwenberge V P, Juniper EF. Compare the efficacy, safety and quality of life provided by Fexofenadine Hydrochloride 120mg, Loratadine 10mg and placebo administered once a daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2009; 30 (6): 891 – 900.
23. Glass DJ, Harper AS. Assessing satisfaction with Desloratadine and Fexofenadine in allergy patients who report dissatisfaction with Loratadine. BMC Family Practice 2003; 4:10.study of efficacy and safety. Arch Otolaryngol Head Neck Surg. Aug 2010; 136(8):796-800.
Sailaxmi V, Rani V.Comparative evaluation of safety and efficacy of oral Rupatadine with oral Fexofenadine in patients of seasonal allergic rhinitis.Perspectives in medical research 2016;4(3):12-16.